retatrutide clinical trial results weight loss Eli Lilly's Phase 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial loss. Read about the work via the link in the comments retatrutide clinical trial benefits New

Battling addictive behavior is challenging overall, but can a known solution for one problem lead to lasting help for another

Why are people talking about compounded GLP-1s

The platform combines prescription medications with in-app support from clinicians to help you achieve your health goals

2001 showed ipamorelin at 100 g/kg three times daily subcutaneously for three months counteracted glucocorticoid-induced bone loss in rats, with periosteal bone formation rate increasing 4-fold versus glucocorticoid alone

The microdosing program targets men who need to lose a modest amount of weight, typically 10 to 20 pounds